Search

Your search keyword '"Plouvier, Emmanuel"' showing total 155 results
Start Over Author "Plouvier, Emmanuel"
155 results on '"Plouvier, Emmanuel"'

1. Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials

Author

Simon, Pauline, Suciu, Stefan, Clappier, Emmanuelle, Cave, Hélène, Sirvent, Nicolas, Plat, Geneviève, Thyss, Antoine, Mechinaud, Françoise, Costa, Vitor M., Ferster, Alina, Lutz, Patrick, Mazingue, Françoise, Plantaz, Dominique, Plouvier, Emmanuel, Bertrand, Yves, Benoit, Yves, Dastugue, Nicole, Rohrlich, Pierre S., and on behalf of the Children’s Leukemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC)

Published
2016
Full Text
View/download PDF

3. Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881

Author

Sirvent, Nicolas, Suciu, Stefan, Rialland, Xavier, Millot, Frédéric, Benoit, Yves, Plantaz, Dominique, Ferster, Alice, Robert, Alain, Lutz, Patrick, Nelken, Brigitte, Plouvier, Emmanuel, Norton, Lucilia, Bertrand, Yves, and Otten, Jacques

Published
2011
Full Text
View/download PDF

4. Familial history of cancer and childhood acute leukemia: a French population-based case-control study

Author

Ripert, Mahaut, Menegaux, Florence, Perel, Yves, Méchinaud, Françoise, Plouvier, Emmanuel, Gandemer, Virginie, Lutz, Patrick, Vannier, Jean-Pierre, Lamagnére, Jean-Pierre, Margueritte, Geneviève, Boutard, Patrick, Robert, Alain, Armari-Alla, Corinne, Munzer, Martine, Millot, Frédéric, de Lumley, Lionel, Berthou, Christian, Rialland, Xavier, Pautard, Brigitte, and Clavel, Jacqueline

Published
2007

7. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease

Author

Bernaudin, Françoise, Socie, Gérard, Kuentz, Mathieu, Chevret, Sylvie, Duval, Michel, Bertrand, Yves, Vannier, Jean-Pierre, Yakouben, Karima, Thuret, Isabelle, Bordigoni, Pierre, Fischer, Alain, Lutz, Patrick, Stephan, Jean-Louis, Dhedin, Nathalie, Plouvier, Emmanuel, Margueritte, Geneviève, Bories, Dominique, Verlhac, Suzanne, Esperou, Hélène, Coic, Lena, Vernant, Jean-Paul, and Gluckman, Eliane

Published
2007
Full Text
View/download PDF

10. Cutaneous involvement in children with acute lymphoblastic leukemia or lymphoblastic lymphoma

Author

Millot, Frederic, Robert, Alain, Bertrand, Yves, Mechinaud, Francoise, Laureys, Genevieve, Ferster, Alice, Brock, Penelope, Rohrlich, Pierre, Mazingue, Francoise, Plantaz, Dominique, Plouvier, Emmanuel, Pacquement, Helene, Behar, Catherine, Rialland, Xavier, Chantraine, Jean-Marie, Guilhot, Francois, and Otten, Jacques

Subjects
Cutaneous manifestations of general diseases -- Statistics, Lymphoblastic leukemia in children -- Complications, Skin lesions -- Causes of
Abstract

Children with acute lymphoblastic leukemia or lymphoblastic lymphoma may develop skin lesions as the initial symptom of the cancer. Of 1,359 children with these types of cancer in one study, 24 had skin lesions at the time of their cancer diagnosis. In three children, the skin lesions preceded the diagnosis by three to eight months. Of the 24, 21 had at least one skin lesion on their head. Skin lesions were just as likely to occur in those with moderate disease as those with severe disease. Seventeen of the 24 children went into remission., ABSTRACT. Objective. Skin involvement in children with acute monocytic leukemia or CD30-positive anaplastic large-cell lymphoma is well-known. In contrast, very little is known about the malignant cutaneous infiltrates in children with acute lymphoblatic leukemia (ALL) or lymphoblastic lymphoma (LBL). This study was designed to determine the frequency of these specific lesions in childhood ALL or LBL and the characteristics of such patients. Design. We studied the clinical and biological findings of children with cutaneous involvement at initial diagnosis of ALL or LBL enrolled between August 1989 and March 1995 in the multicentric trial 58881 of the Children's Leukemia Cooperative Group of the European Organization of Research and Treatment of Cancer (EORTC). Results. Among the 1359 children enrolled in the multicenter trial EORTC 58881, 24 presented with skin involvement at diagnosis. ALL was diagnosed in 15 patients and LBL in 9. In 15 cases, skin lesions were observed within a median time of 6 weeks (range, a few days to 8 months) before the diagnosis of the hematologic disease. Twenty-one children had at least one skin lesion located on the head. Diffuse cutaneous lesions were observed in 7 infants with high-risk ALL. Seventeen of the 24 children remain in the first complete remission (median follow-up of 3 years, range 2 months to 5 years) and 3 are in the second remission with a follow-up of 14 to 24 months. Conclusion. The present study demonstrates that cutaneous involvement can be an early manifestation of ALL or LBL. Cutaneous leukemic infiltrates can be observed in children with standard risk as well as in high-risk ALL. Cutaneous involvement in children with LBL is mainly associated with a B-cell precursor immunophenotype of the lymphomatous cells. The most frequent location of skin lesions in children with ALL or LBL is on the head. Further studies are needed to evaluate the prognosis of children with such involvement at diagnosis. Pediatrics 1997;100:60-64; lymphoblastic leukemia, lymphoblastic lymphoma, children, skin leukemia, skin disease., Skin involvement can be the initial symptom of hematologic diseases in children.[1] Cutaneous infiltrates in children with acute monocytic leukemia or CD30-positive anaplastic large-cell lymphoma is well-known.[2,3] Scant information is [...]

Published
1997

11. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951

Author

Cavé, Hélène, Suciu, Stefan, Preudhomme, Claude, Poppe, Bruce, Robert, Alain, Uyttebroeck, Anne, Malet, Michèle, Boutard, Patrick, Benoit, Yves, Mauvieux, Laurent, Lutz, Patrick, Méchinaud, Françoise, Grardel, Nathalie, Mazingue, Françoise, Dupont, Madeleine, Margueritte, Geneviève, Pages, Marie-Pierre, Bertrand, Yves, Plouvier, Emmanuel, Brunie, Ghislaine, Bastard, Christian, Plantaz, Dominique, Velde, Isabel Vande, Hagemeijer, Anne, Speleman, Frank, Lessard, Michel, Otten, Jacques, Vilmer, Etienne, and Dastugue, Nicole

Published
2004
Full Text
View/download PDF

12. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry

Author

Beaussant Cohen Sarah, Fenneteau Odile, Plouvier Emmanuel, Rohrlich Pierre-Simon, Daltroff Gerard, Plantier Isabelle, Dupuy Alain, Kerob Delphine, Beaupain Blandine, Bordigoni Pierre, Fouyssac Fanny, Delezoide Anne-Lise, Devouassoux Gilles, Nicolas Jean François, Bensaid Philippe, Bertrand Yves, Balabanian Karl, Chantelot Christine Bellanne, Bachelerie Françoise, and Donadieu Jean

Subjects
WHIM, CXCR4, Registry, Neutropenia, Myelokathexis, Infections, Medicine
Abstract

Abstract Background WHIM syndrome (WS), a rare congenital neutropenia due to mutations of the CXCR4 chemokine receptor, is associated with Human Papillomavirus (HPV)-induced Warts, Hypogammaglobulinemia, bacterial Infections and Myelokathexis. The long term follow up of eight patients highlights the clinical heterogeneity of this disease as well as the main therapeutic approaches and remaining challenges in the light of the recent development of new CXCR4 inhibitors. Objective This study aims to describe the natural history of WS based on a French cohort of 8 patients. Methods We have reviewed the clinical, biological and immunological features of patients with WS enrolled into the French Severe Chronic Neutropenia Registry. Results We identified four pedigrees with WS comprised of eight patients and one foetus. Estimated incidence for WS was of 0.23 per million births. Median age at the last visit was 29 years. Three pedigrees encompassing seven patients and the fetus displayed autosomal dominant heterozygous mutations of the CXCR4 gene, while one patient presented a wild-type CXCR4 gene. Two subjects exhibited congenital conotruncal heart malformations. In addition to neutropenia and myelokathexis, all patients presented deep monocytopenia and lymphopenia. Seven patients presented repeated bacterial Ears Nose Throat as well as severe bacterial infections that were curable with antibiotics. Four patients with late onset prophylaxis developed chronic obstructive pulmonary disease (COPD). Two patients reported atypical mycobacteria infections which in one case may have been responsible for one patient’s death due to liver failure at the age of 40.6 years. HPV-related disease manifested in five subjects and progressed as invasive vulvar carcinoma with a fatal course in one patient at the age of 39.5 years. In addition, two patients developed T cell lymphoma skin cancer and basal cell carcinoma at the age of 38 and 65 years. Conclusions Continuous prophylactic anti-infective measures, when started in early childhood, seem to effectively prevent further bacterial infections and the consequent development of COPD. Long-term follow up is needed to evaluate the effect of early anti-HPV targeted prophylaxis on the development of skin and genital warts.

Published
2012
Full Text
View/download PDF

13. Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia

Author

Cave, Helene, van der Werff ten Bosch, Jutte, Suciu, Stefan, Guidal, Christine, Waterkeyn, Christine, Otten, Jacques, Bakkus, Marleen, Thielemans, Kris, Grandchamp, Bernard, Vilmer, Etienne, Nelken, Brigitte, Fournier, Martine, Boutard, Patrick, Lebrun, Emmanuel, Mechinaud, Francoise, Garand, Richard, Robert, Alain, Dastugue, Nicole, Plouvier, Emmanuel, Racadot, Evelyne, Ferster, Alice, Gyselinck, Jan, Fenneteau, Odile, Duval, Michel, Solbu, Gabriel, and Manel, Anne-Marie.

Published
1998
Full Text
View/download PDF

14. Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Societe Francaise de Greffe de Moelle study

Author

Bordigoni, Pierre, Esperou, Helene, Souillet, Gerard, Pico, Jose, Michel, Gerard, Lacour, Brigitte, Reiffers, Josy, Sadoun, Alain, Rohrlich, Pierre, Jouet, Jean-Pierre, Milpied, Noel, Lutz, Patrick, Plouvier, Emmanuel, Cornu, Guy, Vannier, Jean-Pierre, Gandemer, Virginie, Rubie, Herve, Gratecos, Nicole, Leverger, Guy, Stephan, Jean-Louis, Boutard, Patrice, and Vernant, Jean-Paul

Published
1998

15. Validation of the French version of the Childhood Health Assessment Questionnaire (CHAQ) in juvenile idiopathic arthritis

Author

Pouchot, Jacques, Larbre, Jean-Paul, Lemelle, Irène, Sommelet, Danièle, Grouteau, Eric, David, Louis, Duquesne, Agnès, Job Deslandre, Chantal, Kone Paut, Isabelle, Pillet, Pascal, Goumy, Laurence, Barbier, Catherine, Guyot, Marie-Hélène, Mazingue, Françoise, Gandon Laloum, Sylvie, Fischbach, Michel, Quartier, Pierre, Guyot, Claude, Jean, Sylvie, Legall, Edouard, Plouvier, Emmanuel, Bost, Michel, de Lumley, Lionel, Brégeon, Christian, Guillemin, Francis, Coste, Joël, and Prieur, Anne-Marie

Published
2002
Full Text
View/download PDF

16. Validation de la version française du Childhood Health Assessment Questionnaire (CHAQ) dans les arthrites juvéniles idiopathiques

Author

Pouchot, Jacques, Larbre, Jean-Paul, Lemelle, Irène, Sommelet, Danièle, Grouteau, Eric, David, Louis, Duquesne, Agnès, Deslandre, Chantal Job, Paut, Isabelle Kone, Pillet, Pascal, Goumy, Laurence, Barbier, Catherine, Guyot, Marie-Hélène, Mazingue, Françoise, Laloum, Sylvie Gandon, Fischbach, Michel, Quartier, Pierre, Guyot, Claude, Jean, Sylvie, Legall, Edouard, Plouvier, Emmanuel, Bost, Michel, de Lumley, Lionel, Brégeon, Christian, Guillemin, Francis, Coste, Joël, and Prieur, Anne-Marie

Published
2002
Full Text
View/download PDF

18. Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: Final results of the EORTC-CLG randomized phase III trial 58951

Author

Mondelaers, Veerle, Suciu, Stefan, de Moerloose, Barbara, Ferster, Alina, Mazingue, Françoise, Plat, Genevieve, Yakouben, Karima, Uyttebroeck, Anne, Lutz, Patrick, Costa, Vitor, Sirvent, Nicolas, Plouvier, Emmanuel, Munzer, Martine, Poiree, Maryline, Minckes, Odile, Millot, Frédéric, Plantaz, Dominique, Maes, Philip, Hoyoux, Claire, Cavé, Hélène, Rohrlich, Pierre, Bertrand, Yves, Benoit, Yves, Department of Pediatric Hematology-Oncology and Stem Cell Transplantation [Ghent, Belgium], Universiteit Gent = Ghent University [Belgium] (UGENT)-Ghent University Hospital, EORTC Headquarters [Brussels, Belgium], Department of Pediatric Hematology-Oncology [Bruxelles, Belgium], Université libre de Bruxelles (ULB)-Children's University Hospital Queen Fabiola [Bruxelles, Belgium], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Unité d'Hémato-Immunologie pédiatrique [Hôpital Robert Debré, Paris], Service d'Immuno-hématologie pédiatrique [Hôpital Robert Debré, Paris], Hôpital Robert Debré-Hôpital Robert Debré, Department of Pediatric Hematology- Oncology [Leuven, Belgium], University Hospital Gasthuisberg, Hôpital de Hautepierre [Strasbourg], Department of Pediatrics [Porto, Portugal], Portuguese Oncology Institute, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Service de pédiatrie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Département d'hémato-oncologie pédiatrique [Hôpital American Memorial, Reims], Hôpital American Memorial [Reims], Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Département de pédiatrie, CHU Grenoble-Hôpital Michallon, Service de Pédiatrie [HU Antwerp, Belgium], Antwerp University Hospital [Edegem] (UZA), Service de Pédiatrie [CHR de la Citadelle, Liège, Belgium], Centre Hospitalier Régional de la Citadelle [Liège, Belgium] (CHR de la Citadelle), Unité fonctionnelle de génétique clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Hémopathies Myéloïdes : Cellules Souches, Modèles Pré-Cliniques et Recherche Translationnelle (UMR 1131), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] (IHOPe), Hospices Civils de Lyon (HCL), European Org Res Treatment Canc, Universiteit Gent = Ghent University (UGENT)-Ghent University Hospital, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), University Hospital Gasthuisberg [Leuven], and Herrada, Anthony

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, MINIMAL RESIDUAL DISEASE, CHILDREN, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, [SDV.CAN] Life Sciences [q-bio]/Cancer, Medicine and Health Sciences, ONCOLOGY-GROUP, EXPOSURE, ERWINIA-ASPARAGINASE, RISK, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, Science & Technology, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, INDUCTION THERAPY, CANCER, DEXAMETHASONE, REDUCTION, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Human medicine, Life Sciences & Biomedicine, Hématologie
Abstract

Asparaginase is an essential component of combination chemotherapy for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma. The value of asparaginase was further addressed in a group of non-very high-risk patients by comparing prolonged (long-asparaginase) versus standard (short-asparaginase) native E. coli asparaginase treatment in a randomized part of the phase III 58951 trial of the European Organization for Research and Treatment of Cancer Children’s Leukemia Group. The main endpoint was disease-free survival. Overall, 1,552 patients were randomly assigned to long-asparaginase (775 patients) or short-asparaginase (777 patients). Patients with grade ≥2 allergy to native E. coli asparaginase were switched to equivalent doses of Erwinia or pegylated E. coli asparaginase. The 8-year disease-free survival rate (±standard error) was 87.0±1.3% in the long-asparaginase group and 84.4±1.4% in the short-asparaginase group (hazard ratio: 0.87; P=0.33) and the 8-year overall survival rate was 92.6±1.0% and 91.3±1.2% respectively (hazard ratio: 0.89; P=0.53). An exploratory analysis suggested that the impact of long-asparaginase was beneficial in the National Cancer Institute standard-risk group with regards to disease-free survival (hazard ratio: 0.70; P=0.057), but far less so with regards to overall survival (hazard ratio: 0.89). The incidences of grade 3-4 infection during consolidation (25.2% versus 14.4%) and late intensification (22.6% versus 15.9%) and the incidence of grade 2-4 allergy were higher in the long-asparaginase arm (30% versus 21%). Prolonged native E. coli asparaginase therapy in consolidation and late intensification for our non-very high-risk patients did not improve overall outcome but led to an increase in infections and allergy., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2017
Full Text
View/download PDF

20. Pharmacokinetic and Pharmacodynamic Characterization of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01 51851 7)

Author

Thomas, Xavier, Bertrand, Yves, Baruchel, Andre, Blin, Nicolas, Tavernier, Emmanuelle, Ducassou, Stephane, Norbert Vey, Gandemer, Virginie, Cacheux, Victoria, Mazingue, Francoise, Raffoux, Emmanuel, Plat, Genevieve, Fernandes, Jose, Poiree, Maryline, Fornecker, Luc, Stephan, Jean-Louis, Hunault, Mathilde, Auvrignon, Anne, Leguay, Thibault, Lepretre, Stephane, Ferster, Alina, Pellier, Isabelle, Plouvier, Emmanuel, Schmitt, Claudine, Bonin, Cecile, Godfrin, Yann, El Hariry, Iman, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Hématologie et immunologie pédiatrique, Hospices Civils de Lyon (HCL)-CHU Lyon-Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] (IHOPe), Hospices Civils de Lyon (HCL)-Hôpital Femme-Mère-Enfant (HFME), Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Hôpital Pellegrin Tripode, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Pediatric Onco-Hematology Unit, CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), CHU Clermont-Ferrand, Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Pédiatrie, Unité d'Oncologie et Hématologie Pédiatrique, Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'hématologie pédiatrique, CHU Saint-Etienne, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Trousseau [APHP], Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pédiatrie, CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'Hématologie Pédiatrique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV]Life Sciences [q-bio]
Abstract

WOS:000368020102004; International audience; Conference: 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL - DEC 05-08, 2015

Published
2015

21. Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials

Author

Simon, Pauline, Suciu, Stefan, Clappier, Emmanuelle, Cavé, Hélène, Sirvent, Nicolas, Plat, Genevieve, Thyss, Antoine, Méchinaud, Françoise, Costa, Vitor M., Ferster, Alina, Lutz, Patrick, Mazingue, Françoise, Plantaz, Dominique, Plouvier, Emmanuel, Bertrand, Yves, Benoit, Yves, Dastugue, Nicole, Rohrlich, Pierre S., Europea, Childrens Leukemia Grp CLG, Département de génétique [Robert Debré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Pédiatrie, Unité d'Oncologie et Hématologie Pédiatrique, Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Toulouse [Toulouse], Haematology, Children's Cancer Center, The Royal Children's Hospital, Hôpital Universitaire des Enfants Reine Fabiola [Bruxelles, Belgique] (HUDERF), Service de pédiatrie, CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service Hématologie Infantile, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hématologie et immunologie pédiatrique, Hospices Civils de Lyon (HCL)-CHU Lyon-Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] (IHOPe), Hospices Civils de Lyon (HCL)-Hôpital Femme-Mère-Enfant (HFME), and Laboratoire d'Hématologie

Subjects
Male, Pediatrics, medicine.medical_specialty, Adolescent, T cell, [SHS.PSY]Humanities and Social Sciences/Psychology, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Translocation, Genetic, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Prospective Studies, Prospective cohort study, Child, Survival rate, Retrospective Studies, Chromosomes, Human, Pair 14, business.industry, Chromosomes, Human, Pair 11, Cancer, Retrospective cohort study, Hematology, General Medicine, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, medicine.disease, 3. Good health, Survival Rate, Leukemia, medicine.anatomical_structure, Treatment Outcome, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, 030220 oncology & carcinogenesis, Child, Preschool, Quality of Life, Prednisolone, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, business, 030215 immunology, medicine.drug, Cohort study
Abstract

International audience; Acute lymphoblastic leukemia of T cell lineage (T-ALL) is an aggressive ă malignant disease which accounts for 15 % of childhood ALL. T(11;14) is ă the more frequent chromosomal abnormality in childhood T-ALL, but its ă prognostic value remained controversial. Our aim was to analyze the ă outcome of childhood T-ALL with t(11;14) to know if the presence of this ă translocation is associated with a poor prognosis. We conducted a ă retrospective study from a series of 20 patients with t(11;14), treated ă in two consecutive trials from the European Organization for Research ă and Treatment of Cancer Children Leukemia Group over a 19-year period ă from 1989 to 2008. There were no significant differences between the 2 ă consecutive groups of patients with t(11;14) regarding the clinical and ă biological features at diagnosis. Among 19 patients who reached complete ă remission, 9 patients relapsed. We noticed 7 deaths all relapse- or ă failure-related. In the 58881 study, a presence of t(11;14) was ă associated with a poor outcome with an event-free survival at 5 years at ă 22.2 % versus 65.1 % for the non-t(11;14) T-ALL (p = 0.0004). In the ă more recent protocol, the outcome of T-ALL with t(11;14) reached that of ă non-t(11;14) T-ALL with an event-free survival at 5 years at 65.5 versus ă 74.9 % (p = 0.93). The presence of t(11;14) appeared as a poor ă prognostic feature in the 58881 trial whereas this abnormality no longer ă affected the outcome in the 58951 study. This difference is probably ă explained by the more intensive chemotherapy in the latest trial.

Published
2015
Full Text
View/download PDF

22. Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study

Author

Clement, Laura, primary, Suciu, Stefan, additional, Luquet, Isabelle, additional, Ferster, Alina, additional, Yakouben, Karima, additional, Uytterbroeck, Anne, additional, Paillard, Catherine, additional, Sirvent, Nicolas, additional, Costa, Vitor, additional, De Moerloose, Barbara, additional, Mazingue, Francoise, additional, Plouvier, Emmanuel, additional, Munzer, Martine, additional, Poirée, Maryline, additional, Minckes, Odile, additional, Millot, Frédéric, additional, Plantaz, Dominique, additional, Piette, Caroline, additional, Speleman, Frank, additional, Cavé, Hélène, additional, VanderWerff-tenBossch, Jutte, additional, Rohrlich, Pierre Simon, additional, Bertrand, Yves, additional, Benoit, Yves, additional, and Plat, Geneviève, additional

Published
2016
Full Text
View/download PDF

23. Cutaneous malignant melanoma in children and adolescents treated in pediatric oncology units

Author

Réguerre, Yves, primary, Vittaz, Marie, additional, Orbach, Daniel, additional, Robert, Caroline, additional, Bodemer, Christine, additional, Mateus, Christina, additional, Plantaz, Dominique, additional, Plouvier, Emmanuel, additional, Lutz, Patrick, additional, Rakotonjanahary, Josue, additional, Fraitag, Sylvie, additional, and Martin, Ludovic, additional

Published
2016
Full Text
View/download PDF

24. Expanded Access Program of GRASPA for treatment of patients with acute lymphoblastic leukemia unable to receive other form of L-Asparaginase: A status update (NCT02197650).

Author

Bertrand, Yves, primary, Dombret, Herve, additional, Quesnel, Bruno, additional, Lissandre, Severine, additional, Schmitt, Claudine, additional, Plouvier, Emmanuel, additional, Recher, Christian, additional, Poiree, Maryline, additional, DUMESNIL de MARICOURT, Cecile, additional, and El-Hariry, Iman, additional

Published
2016
Full Text
View/download PDF

25. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.

Author

Clappier, E, Grardel, Nathalie, Bakkus, M, Rapion, J, De Moerloose, B, Kastner, Philippe, Caye, A, Vivent, Jocelyne, Costa, V, Ferster, Alina, Lutz, P, Mazingue, F, Millot, Frédéric, Plantaz, D, Plat, G, Plouvier, Emmanuel, Poirée, Marilyne, Sirvent, Nicolas, Uyttebroeck, Anne, Yakouben, Karima, Girard, S, Dastugue, Nicole, Suciu, S, Benoît, Yves, Bertrand, Yves, Cavé, H, Children’s Leukemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC), Clappier, E, Grardel, Nathalie, Bakkus, M, Rapion, J, De Moerloose, B, Kastner, Philippe, Caye, A, Vivent, Jocelyne, Costa, V, Ferster, Alina, Lutz, P, Mazingue, F, Millot, Frédéric, Plantaz, D, Plat, G, Plouvier, Emmanuel, Poirée, Marilyne, Sirvent, Nicolas, Uyttebroeck, Anne, Yakouben, Karima, Girard, S, Dastugue, Nicole, Suciu, S, Benoît, Yves, Bertrand, Yves, Cavé, H, and Children’s Leukemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC)

Abstract

The added value of IKZF1 gene deletion (IKZF1(del)) as a stratifying criterion in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is still debated. We performed a comprehensive analysis of the impact of IKZF1(del) in a large cohort of children (n=1223) with BCR-ABL1-negative BCP-ALL treated in the EORTC-CLG trial 58951. Patients with IKZF1(del) had a lower 8-year event-free survival (EFS, 67.7% versus 86.5%; hazard ratio (HR)=2.41; 95% confidence interval (CI)=1.75-3.32; P<0.001). Importantly, despite association with high-risk features such as high minimal residual disease, IKZF1(del) remained significantly predictive in multivariate analyses. Analysis by genetic subtype showed that IKZF1(del) increased risk only in the high hyperdiploid ALLs (HR=2.57; 95% CI=1.19-5.55; P=0.013) and in 'B-other' ALLs, that is, lacking classifying genetic lesions (HR=2.22; 95% CI=1.45-3.39; P<0.001), the latter having then a dramatically low 8-year EFS (56.4; 95% CI=44.6-66.7). Among IKZF1(del)-positive patients randomized for vincristine-steroid pulses during maintenance, those receiving pulses had a significantly higher 8-year EFS (93.3; 95% CI=61.3-99.0 versus 42.1; 95% CI=20.4-62.5). Thus, IKZF1(del) retains independent prognostic significance in the context of current risk-adapted protocols, and is associated with a dismal outcome in 'B-other' ALL. Addition of vincristine-steroid pulses during maintenance may specifically benefit to IKZF1(del) patients in preventing relapses., info:eu-repo/semantics/published

Published
2015

26. CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol

Author

Ghazavi, Farzaneh, Bertrand, Yves, Minckes, Odile, Costa, Vitor, Ferster, Alina, Mazingue, Françoise, Plat, Geneviève, Plouvier, Emmanuel, Poirée, Marilyne, Uyttebroeck, Anne, van der Werff Ten Bosch, Jutte, Clappier, Emmanuelle, Yakouben, Karima, Helsmoortel, Hetty, Meul, Magali, Van Roy, Nadine, Philippé, Jan, Speleman, Frank, Cavé, Hélène, Van Vlierberghe, Pieter, De Moerloose, Barbara, Lammens, Tim, Suciu, Stefan, Caye, Aurélie, Zegrari, Samira, Bakkus, Marleen, Grarde, Nathalie, Benoît, Yves, Ghazavi, Farzaneh, Bertrand, Yves, Minckes, Odile, Costa, Vitor, Ferster, Alina, Mazingue, Françoise, Plat, Geneviève, Plouvier, Emmanuel, Poirée, Marilyne, Uyttebroeck, Anne, van der Werff Ten Bosch, Jutte, Clappier, Emmanuelle, Yakouben, Karima, Helsmoortel, Hetty, Meul, Magali, Van Roy, Nadine, Philippé, Jan, Speleman, Frank, Cavé, Hélène, Van Vlierberghe, Pieter, De Moerloose, Barbara, Lammens, Tim, Suciu, Stefan, Caye, Aurélie, Zegrari, Samira, Bakkus, Marleen, Grarde, Nathalie, and Benoît, Yves

Abstract

DNA copy number analysis has been instrumental for the identification of genetic alterations in B-cell precursor acute lymphoblastic leukemia. Notably, some of these genetic defects have been associated with poor treatment outcome and might be relevant for future risk stratification. In this study, we characterized recurrent deletions of CD200 and BTLA genes, mediated by recombination-activating genes, and used breakpoint-specific polymerase chain reaction assay to screen a cohort of 1154 cases of B-cell precursor acute lymphoblastic leukemia uniformly treated according to the EORTC-CLG 58951 protocol. CD200/BTLA deletions were identified in 56 of the patients (4.8%) and were associated with an inferior 8-year event free survival in this treatment protocol [70.2% ± 1.2% for patients with deletions versus 83.5% ± 6.4% for non-deleted cases (hazard ratio 2.02; 95% confidence interval 1.23-3.32; P=0.005)]. Genetically, CD200/BTLA deletions were strongly associated with ETV6-RUNX1-positive leukemias (P<0.0001), but were also identified in patients who did not have any genetic abnormality that is currently used for risk stratification. Within the latter population of patients, the presence of CD200/BTLA deletions was associated with inferior event-free survival and overall survival. Moreover, the multivariate Cox model indicated that these deletions had independent prognostic impact on event-free survival when adjusting for conventional risk criteria. All together, these findings further underscore the rationale for copy number profiling as an important tool for risk stratification in human B-cell precursor acute lymphoblastic leukemia. This trial was registered at www.ClinicalTrials.gov as, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2015

27. Expanded Access Program of Graspa for Treatment of Patients with Acute Lymphoblastic Leukemia Unable to Receive Other Form of L-Asparaginase - a Status Update (NCT02197650)

Author

Bertrand, Yves, primary, Dombret, Hervé, additional, Quesnel, Bruno, additional, Stephan, Jean-Louis, additional, Schmitt, Claudine, additional, Lissandre, Severine, additional, Poiree, Maryline, additional, Recher, Christian, additional, Plouvier, Emmanuel, additional, Dumesnil de Maricourt, Cécile, additional, Salako, David, additional, Godfrin, Yann, additional, and El Hariry, Iman, additional

Published
2015
Full Text
View/download PDF

28. Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)

Author

Baruchel, Andre, primary, Bertrand, Yves, additional, Thomas, Xavier, additional, Blin, Nicolas, additional, Tavernier, Emmanuelle, additional, Ducassou, Stephane, additional, Vey, Norbert, additional, Gandemer, Virginie, additional, Cacheux, Victoria, additional, Mazingue, Francoise, additional, Raffoux, Emmanuel, additional, PLAT, Genevieve, additional, Fernandes, Jose, additional, Maryline, Poiree, additional, Fornecker, Luc, additional, Stephan, Jean-Louis, additional, Hunault, Mathilde, additional, Auvrignon, Anne, additional, Leguay, Thibault, additional, Plantaz, Dominique, additional, Lepretre, Stephane, additional, Ferster, Alina, additional, Pellier, Isabelle, additional, Plouvier, Emmanuel, additional, Schmitt, Claudine, additional, Bonin, Cecile, additional, and El Hariry, Iman, additional

Published
2015
Full Text
View/download PDF

29. t(12;21)/ETV6 -RUNX1 Confers a Specific Pattern of In Vivo Sensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and 58951 of the EORTC Children Leukemia Group

Author

Piette, Caroline, primary, Suciu, Stefan, additional, Clappier, Emmanuelle, additional, Bertrand, Yves, additional, Plat, Genevieve, additional, Chantrain, Christophe, additional, Costa, Vitor, additional, Dastugue, Nicole, additional, Ferster, Alina, additional, Gilotay, Caroline, additional, Girard, Sandrine, additional, Grardel, Nathalie, additional, Lutz, Patrick, additional, Mazingue, Francoise, additional, Minckes, Odile, additional, Munzer, Martine, additional, Plouvier, Emmanuel, additional, Sirvent, Nicolas, additional, Uyttebroeck, Anne, additional, van Roy, Nadine, additional, Yakouben, Karima, additional, Benoit, Yves, additional, and Cavé, Hélène, additional

Published
2015
Full Text
View/download PDF

30. Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)

Author

Bertrand, Yves, primary, Baruchel, Andre, additional, Thomas, Xavier, additional, Blin, Nicolas, additional, Tavernier, Emmanuelle, additional, Ducassou, Stephane, additional, Vey, Norbert, additional, Gandemer, Virginie, additional, Cacheux, Victoria, additional, Mazingue, Francoise, additional, Raffoux, Emmanuel, additional, Plat, Genevieve, additional, Fernandes, Jose, additional, Poiree, Maryline, additional, Fornecker, Luc, additional, Stephan, Jean-Louis, additional, Hunault, Mathilde, additional, Auvrignon, Anne, additional, Leguay, Thibault, additional, Plantaz, Dominique, additional, Lepretre, Stephane, additional, Ferster, Alina, additional, Pellier, Isabelle, additional, Plouvier, Emmanuel, additional, Schmitt, Claudine, additional, Bonin, Cecile, additional, Godfrin, Yann, additional, and El Hariry, Iman, additional

Published
2015
Full Text
View/download PDF

31. Prognostic Relevance of CD200/Btla Deletions in Pediatric Precursor-B Cell Acute Lymphoblastic Leukemia Treated According to the EORTC-CLG 58951 Protocol

Author

Ghazavi, Farzaneh, primary, Lammens, Tim, additional, Clappier, Emmanuelle, additional, Suciu, Stefan, additional, Caye, Aurélie, additional, Zegrari, Samira, additional, Bakkus, Marleen, additional, Grardel, Nathalie, additional, Benoit, Yves, additional, Bertrand, Yves, additional, Minckes, Odile, additional, Costa, Vitor, additional, Ferster, Alina, additional, Mazingue, Françoise, additional, Plat, Geneviève, additional, Plouvier, Emmanuel, additional, Poirée, Marilyne, additional, Uyttebroeck, Anne, additional, Van der Werff Ten Bosch, Jutte, additional, Helsmoortel, Hetty, additional, Meul, Magali, additional, Van Roy, Nadine, additional, Philippé, Jan, additional, Speleman, Frank, additional, Cavé, Hélène, additional, Van Vlierberghe, Pieter, additional, and De Moerloose, Barbara, additional

Published
2014
Full Text
View/download PDF

32. Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours.

Author

Renard, Marleen, Suciu, Stefan, Bertrand, Yves, Uyttebroeck, Anne, Ferster, Alina, van der Werff Ten Bosch, Jutte, Mazingue, F, Plouvier, Emmanuel, Robert, Alain, Boutard, Patrick, Millot, Frédéric, Munzer, Martine, Mechinaud, F, Lescoeur, Brigitte, Baila, L., Vandecruys, Els, Benoît, Yves, Philippet, Pierre, EORTC Children Leukaemia Group (CLG), Renard, Marleen, Suciu, Stefan, Bertrand, Yves, Uyttebroeck, Anne, Ferster, Alina, van der Werff Ten Bosch, Jutte, Mazingue, F, Plouvier, Emmanuel, Robert, Alain, Boutard, Patrick, Millot, Frédéric, Munzer, Martine, Mechinaud, F, Lescoeur, Brigitte, Baila, L., Vandecruys, Els, Benoît, Yves, Philippet, Pierre, and EORTC Children Leukaemia Group (CLG)

Abstract

Intensive chemotherapy has markedly improved the survival of children with acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LL). Evaluation of late effects and analysis of factors contributing to their occurrence has become of major importance. Second neoplasm (SN) belongs to the most severe late events., Comparative Study, Journal Article, Multicenter Study, Research Support, N.I.H. Extramural, Research Support, Non-U.S. Gov't, FLWIN, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2011

33. Corrigendum to “Risk adapted chemotherapy for localised Ewing’s sarcoma of bone: The French EW93 study” [Eur. J. Cancer 48 (9) (2012) 1376–1385]

Author

Gaspar, Nathalie, primary, Rey, Annie, additional, Bérard, Perrine Marec, additional, Michon, Jean, additional, Gentet, Jean Claude, additional, Tabone, Marie Dominique, additional, Roché, Henri, additional, Defachelles, Anne Sophie, additional, Lejars, Odile, additional, Plouvier, Emmanuel, additional, Schmitt, Claudine, additional, Bui, Binh, additional, Boutard, Patrick, additional, Taque, Sophie, additional, Munzer, Martine, additional, Vannier, Jean-Pierre, additional, Plantaz, Dominique, additional, Entz-Werle, Natacha, additional, and Oberlin, Odile, additional

Published
2013
Full Text
View/download PDF

34. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report.

Author

Entz-Werle, N, Suciu, Stefan, van der Werff Ten Bosch, Jutte, Vilmer, E, Bertrand, Yves, Benoît, Yves, Margueritte, Geneviève, Plouvier, Emmanuel, Boutard, Patrick, Vandecruys, Els, Ferster, Alina, Lutz, Pierre, Uyttebroeck, Anne, Hoyoux, C, Thyss, Antoine, Rialland, X, Norton, Larry, Pages, M-P, Philippe, N, Otten, Jacques, Behar, C, EORTC Children Leukemia Group, Entz-Werle, N, Suciu, Stefan, van der Werff Ten Bosch, Jutte, Vilmer, E, Bertrand, Yves, Benoît, Yves, Margueritte, Geneviève, Plouvier, Emmanuel, Boutard, Patrick, Vandecruys, Els, Ferster, Alina, Lutz, Pierre, Uyttebroeck, Anne, Hoyoux, C, Thyss, Antoine, Rialland, X, Norton, Larry, Pages, M-P, Philippe, N, Otten, Jacques, Behar, C, and EORTC Children Leukemia Group

Abstract

The first EORTC (European Organization of Research and Treatment of Cancer) acute myeloblastic leukemia (AML) pilot study (58872) was conducted between January 1988 and December 1991. Out of 108 patients, 78% achieved complete remission (CR), and event-free survival (EFS) and survival rates (s.e. %) at 7 years were 40 (5) and 51% (6%), respectively. It indicated that mitoxantrone could be substituted for conventional anthracyclines in the treatment of childhood AML without inducing cardiotoxicity. The aim of the next EORTC 58921 trial was to compare the efficacy and toxicity of idarubicin vs mitoxantrone in initial chemotherapy courses, further therapy consisting of allogeneic bone marrow transplantation (alloBMT) in patients with an HLA-compatible sibling donor or chemotherapy in patients without a donor. Out of 177 patients, recruited between October 1992 and December 2002, 81% reached CR. Overall 7-year EFS and survival rates were 49 (4) and 62% (4%), respectively. Out of 145 patients who received the first intensification, 39 had a sibling donor. In patients with or without a donor, the 7-year disease-free survival (DFS) rate was 63 (8) and 57% (5%) and the 7-year survival rate was 78 (7) and 65% (5%), respectively. Patients with favorable, intermediate and unfavorable cytogenetic features had a 5-year EFS rate of 57, 45 and 45% and a 5-year survival rate of 89, 67 and 53%, respectively., Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H. Extramural, Research Support, Non-U.S. Gov't, info:eu-repo/semantics/published

Published
2005

35. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG.

Author

van der Werff Ten Bosch, Jutte, Suciu, Stefan, Thyss, Antoine, Bertrand, Yves, Norton, Lucilia, Mazingue, F, Uyttebroeck, Anne, Lutz, Pierre, Robert, Alain, Boutard, Patrick, Ferster, Alina, Plouvier, Emmanuel, Maes, Peggy, Munzer, Martine, Plantaz, D, Dresse, Marie-Françoise, Philippet, Pierre, Sirvent, Nicolas, Waterkeyn, C, Vilmer, E, Philippe, N, Otten, Jacques, van der Werff Ten Bosch, Jutte, Suciu, Stefan, Thyss, Antoine, Bertrand, Yves, Norton, Lucilia, Mazingue, F, Uyttebroeck, Anne, Lutz, Pierre, Robert, Alain, Boutard, Patrick, Ferster, Alina, Plouvier, Emmanuel, Maes, Peggy, Munzer, Martine, Plantaz, D, Dresse, Marie-Françoise, Philippet, Pierre, Sirvent, Nicolas, Waterkeyn, C, Vilmer, E, Philippe, N, and Otten, Jacques

Abstract

Between November 1990 and November 1996, EORTC Children Leukemia Group conducted a randomized trial in de novo acute lymphoblastic leukemia and lymphoblastic non-Hodgkin's lymphoma patients using a Berlin-Frankfurt-Munster protocol to evaluate the monthly addition of intravenous 6-mercaptopurine (i.v. 6-MP) (1 g/m(2)) to conventional continuation therapy comprising per oral MTX weekly and 6-MP daily. Only during the first 18 months of the randomization period, 6-MP p.o. was interrupted for 1 week after each i.v. 6-MP. A total of 877 patients was randomized to either no i.v. 6-MP (Arm A) or additional i.v. 6-MP (Arm B). A total of 217 relapses (91 in Group A vs 128 in Group B) and 13 deaths in CR (5 vs 8) were reported; a total of 134 patients (55 vs 79) died. The median follow-up was 7.6 years. At 8 years, the disease-free survival rate was lower (P=0.005) in Arm B (69.1% (s.e.=2.2%)) than in Arm A (77.9% (s.e.=2.0%)), and the hazard ratio was 1.45 (95% CI 1.12-1.89). In conclusion, as delivered in this study, i.v. 6-MP was detrimental to event-free survival., Clinical Trial, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, N.I.H. Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., info:eu-repo/semantics/published

Published
2005

36. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry

Author

Solly, Françoise, primary, Angelot, Fanny, additional, Garand, Richard, additional, Ferrand, Christophe, additional, Seillès, Estelle, additional, Schillinger, Françoise, additional, Decobecq, Agnès, additional, Billot, Maryse, additional, Larosa, Fabrice, additional, Plouvier, Emmanuel, additional, Deconinck, Eric, additional, Legrand, Faezeh, additional, Saas, Philippe, additional, Rohrlich, Pierre-Simon, additional, and Garnache-Ottou, Francine, additional

Published
2011
Full Text
View/download PDF

37. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.

Author

Millot, Frédéric, Suciu, Stefan, Philippe, N, Benoît, Yves, Mazingue, F, Uyttebroeck, Anne, Lutz, Pierre, Mechinaud, F, Robert, Alain, Boutard, Patrick, Marguerite, Geneviève, Ferster, Alina, Plouvier, Emmanuel, Rialland, X, Behard, C, Plantaz, D, Dresse, Marie-Françoise, Philippet, Pierre, Norton, Lucilia, Thyss, Antoine, Dastugue, Nicole, Waterkeyn, C, Vilmer, E, Otten, Jacques, Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer, Millot, Frédéric, Suciu, Stefan, Philippe, N, Benoît, Yves, Mazingue, F, Uyttebroeck, Anne, Lutz, Pierre, Mechinaud, F, Robert, Alain, Boutard, Patrick, Marguerite, Geneviève, Ferster, Alina, Plouvier, Emmanuel, Rialland, X, Behard, C, Plantaz, D, Dresse, Marie-Françoise, Philippet, Pierre, Norton, Lucilia, Thyss, Antoine, Dastugue, Nicole, Waterkeyn, C, Vilmer, E, Otten, Jacques, and Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer

Abstract

The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen., Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S., info:eu-repo/semantics/published

Published
2001

38. Treatment outcome in infant acute lymphoblastic leukemia. Children Leukemia Cooperative Group--EORTC. European Organization for Research and Treatment of Cancer.

Author

Ferster, Alina, Benoît, Yves, Francotte, N, Dresse, Marie-Françoise, Uyttebroeck, Anne, Plouvier, Emmanuel, Thyss, Antoine, Lutz, Pierre, Marguerite, Geneviève, Behar, C, Mazingue, F, Boutard, Patrick, Millot, Frédéric, Rialland, X, Mechinaud, F, Norton, Lucilia, Robert, Alain, Otten, Jacques, Vilmer, E, Philippe, N, Waterkeyn, C, Suciu, Stefan, Ferster, Alina, Benoît, Yves, Francotte, N, Dresse, Marie-Françoise, Uyttebroeck, Anne, Plouvier, Emmanuel, Thyss, Antoine, Lutz, Pierre, Marguerite, Geneviève, Behar, C, Mazingue, F, Boutard, Patrick, Millot, Frédéric, Rialland, X, Mechinaud, F, Norton, Lucilia, Robert, Alain, Otten, Jacques, Vilmer, E, Philippe, N, Waterkeyn, C, and Suciu, Stefan

Abstract

Comment, Letter, SCOPUS: le.j, info:eu-repo/semantics/published

Published
2000

40. Is CDKN2A +/− CDKN2B and MTAP Inactivation of Prognostic Significance in B-Precursor Childhood Acute Lymphoblastic Leukemia? Results of EORTC Studies 58881 and 58951.

Author

Mirebeau, Delphine, primary, Acquaviva, Cécile, primary, Suciu, Stefan, primary, Bertin, Raphaëlle, primary, Robert, Alain, primary, Boutard, Patrick, primary, Méchinaud, Françoise, primary, Plouvier, Emmanuel, primary, Otten, Jacques, primary, Vilmer, Etienne, primary, and Cavé, Hélène, primary

Published
2004
Full Text
View/download PDF

41. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group.

Author

Thyss, Antoine, Suciu, Stefan, Bertrand, Yves, Mazingue, F, Robert, Alain, Vilmer, E, Mechinaud, F, Benoît, Yves, Brock, P, Ferster, Alina, Lutz, Pierre, Boutard, Patrick, Marguerite, Geneviève, Plouvier, Emmanuel, Michel, Gilles, Plantaz, D, Munzer, Martine, Rialland, X, Chantraine, J M, Norton, Lucilia, Solbu, Gabriel, Philippe, N, Otten, Jacques, Thyss, Antoine, Suciu, Stefan, Bertrand, Yves, Mazingue, F, Robert, Alain, Vilmer, E, Mechinaud, F, Benoît, Yves, Brock, P, Ferster, Alina, Lutz, Pierre, Boutard, Patrick, Marguerite, Geneviève, Plouvier, Emmanuel, Michel, Gilles, Plantaz, D, Munzer, Martine, Rialland, X, Chantraine, J M, Norton, Lucilia, Solbu, Gabriel, Philippe, N, and Otten, Jacques

Abstract

The in vivo response to prephase corticosteroid therapy for 1 week has been described as a major prognostic factor in childhood acute lymphoblastic leukemia (ALL). Patients with less than 1,000 blasts/microL at day 8 are considered responders and have a better prognosis. This prephase therapy is usually considered as an evaluation of glucocorticoid sensitivity. In fact, it also includes one intrathecal (IT) injection of methotrexate (MTX). In this study, we try to clarify the influence of this injection of IT MTX on the response to the prephase therapy., Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., info:eu-repo/semantics/published

Published
1997

42. Cutaneous involvement in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. The Children's Leukemia Cooperative Group of the European Organization of Research and Treatment of Cancer (EORTC).

Author

Millot, Frédéric, Robert, Alain, Bertrand, Yves, Mechinaud, F, Laureys, G, Ferster, Alina, Brock, P, Rohrlich, P, Mazingue, F, Plantaz, D, Plouvier, Emmanuel, Pacquement, Hélène, Behar, C, Rialland, X, Chantraine, J M, Guilhot, François, Otten, Jacques, Millot, Frédéric, Robert, Alain, Bertrand, Yves, Mechinaud, F, Laureys, G, Ferster, Alina, Brock, P, Rohrlich, P, Mazingue, F, Plantaz, D, Plouvier, Emmanuel, Pacquement, Hélène, Behar, C, Rialland, X, Chantraine, J M, Guilhot, François, and Otten, Jacques

Abstract

Skin involvement in children with acute monocytic leukemia or CD30-positive anaplastic large-cell lymphoma is well-known. In contrast, very little is known about the malignant cutaneous infiltrates in children with acute lymphoblatic leukemia (ALL) or lymphoblastic lymphoma (LBL). This study was designed to determine the frequency of these specific lesions in childhood ALL or LBL and the characteristics of such patients., Comparative Study, Journal Article, Multicenter Study, info:eu-repo/semantics/published

Published
1997

43. Treatment outcome in infant acute lymphoblastic leukemia

Author

Ferster, Alina, primary, Benoit, Yves, additional, Francotte, Nadine, additional, Dresse, Marie-Françoise, additional, Uyttebroeck, Anne, additional, Plouvier, Emmanuel, additional, Thyss, Antoine, additional, Lutz, Patrick, additional, Marguerite, Geneviève, additional, Behar, Catherine, additional, Mazingue, Françoise, additional, Boutard, Patrick, additional, Millot, Frederic, additional, Rialland, Xavier, additional, Mechinaud, Françoise, additional, Norton, Lucilia, additional, Robert, Alain, additional, Otten, Jacques, additional, Vilmer, Etienne, additional, Philippe, Noel, additional, Waterkeyn, Christine, additional, and Suciu, Stefan, additional

Published
2000
Full Text
View/download PDF

44. Graft Failure after T Cell Depleted HLA Identical Allogeneic Bone Marrow Transplantation: Risk Factors in Leukemic Patients

Author

Delain, Martine, primary, Cahn, Jean-Yves, additional, Racadot, Evelyne, additional, Flesch, Michel, additional, Plouvier, Emmanuel, additional, Mercier, Mariette, additional, Tiberghien, Pierre, additional, Pavy, Jean-Jacques, additional, Deschaseaux, Marie, additional, Deconinck, Eric, additional, Couteret, Yves, additional, Brion, Annie, additional, and Herve, Patrick, additional

Published
1993
Full Text
View/download PDF

46. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry.

Author

Cohen, Sarah Beaussant, Fenneteau, Odile, Plouvier, Emmanuel, Rohrlich, Pierre-Simon, Daltroff, Gerard, Plantier, Isabelle, Dupuy, Alain, Kerob, Delphine, Beaupain, Blandine, Bordigoni, Pierre, Fouyssac, Fanny, Delezoide, Anne-Lise, Devouassoux, Gilles, Nicolas, Jean François, Bensaid, Philippe, Bertrand, Yves, Balabanian, Karl, Chantelot, Christine Bellanne, Bachelerie, Françoise, and Donadieu, Jean

Subjects
NEUTROPENIA, HEALTH outcome assessment, GENETIC mutation, CHEMOKINE receptors, AGAMMAGLOBULINEMIA, WARTS, BACTERIAL diseases
Abstract

Background: WHIM syndrome (WS), a rare congenital neutropenia due to mutations of the CXCR4 chemokine receptor, is associated with Human Papillomavirus (HPV)-induced Warts, Hypogammaglobulinemia, bacterial Infections and Myelokathexis. The long term follow up of eight patients highlights the clinical heterogeneity of this disease as well as the main therapeutic approaches and remaining challenges in the light of the recent development of new CXCR4 inhibitors. Objective: This study aims to describe the natural history of WS based on a French cohort of 8 patients. Methods: We have reviewed the clinical, biological and immunological features of patients with WS enrolled into the French Severe Chronic Neutropenia Registry. Results: We identified four pedigrees with WS comprised of eight patients and one foetus. Estimated incidence for WS was of 0.23 per million births. Median age at the last visit was 29 years. Three pedigrees encompassing seven patients and the fetus displayed autosomal dominant heterozygous mutations of the CXCR4 gene, while one patient presented a wild-type CXCR4 gene. Two subjects exhibited congenital conotruncal heart malformations. In addition to neutropenia and myelokathexis, all patients presented deep monocytopenia and lymphopenia. Seven patients presented repeated bacterial Ears Nose Throat as well as severe bacterial infections that were curable with antibiotics. Four patients with late onset prophylaxis developed chronic obstructive pulmonary disease (COPD). Two patients reported atypical mycobacteria infections which in one case may have been responsible for one patient's death due to liver failure at the age of 40.6 years. HPV-related disease manifested in five subjects and progressed as invasive vulvar carcinoma with a fatal course in one patient at the age of 39.5 years. In addition, two patients developed T cell lymphoma skin cancer and basal cell carcinoma at the age of 38 and 65 years. Conclusions: Continuous prophylactic anti-infective measures, when started in early childhood, seem to effectively prevent further bacterial infections and the consequent development of COPD. Long-term follow up is needed to evaluate the effect of early anti-HPV targeted prophylaxis on the development of skin and genital warts. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

47. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.

Author

Solly, Françoise, Angelot, Fanny, Garand, Richard, Ferrand, Christophe, Seillès, Estelle, Schillinger, Françoise, Decobecq, Agnès, Billot, Maryse, Larosa, Fabrice, Plouvier, Emmanuel, Deconinck, Eric, Legrand, Faezeh, Saas, Philippe, Rohrlich, Pierre-Simon, and Garnache-Ottou, Francine

Abstract

Minimal residual disease (MRD) has emerged as a major prognostic factor for monitoring patients with B-lineage acute lymphoblastic leukemia (B-ALL). The quantification of MRD by flow cytometry (FC) is based on the identification of a leukemia-associated phenotype (LAP). Because phenotypic switch is common during treatment, multiple LAPs must be available and used for MRD detection over time. We evaluated the potential usefulness of CD304 as a new marker for monitoring MRD. CD304 was expressed in 48% of B-ALL (24/50) with discriminative fluorescence intensity compared with CD304-negative normal B-cell precursors ( n = 15). The sensitivity of CD304-based MRD detection reached 10−4, as with some of established LAPs. The stability of CD304 expression evaluated during therapy and at relapse confirms the usefulness of this marker for MRD quantification. Finally, CD304 was repeatedly expressed in patients with TEL-AML1 gene rearrangement, which warrants further investigation on its potential relevance as a prognosis marker or therapeutic target. © 2011 International Society for Advancement of Cytometry [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

49. SOLUBLE CD8 IL2 RECEPTOR AND TUMOR NECROSIS FACTORALPHA LEVELS IN STEROIDRESISTANT ACUTE GRAFTVERSUS-HOST DISEASE

Author

TIBERGHIEN, PIERRE, RACADOT, EVELYNE, LIOURE, BRUNO, DELAIN, MARTINE, GIRARD, ALINE, WIJDENES, JOHN, PLOUVIER, EMMANUEL, FLESCH, MICHEL, CAHN, JEAN-YVES, and HERVE, PATRICK

Abstract

Serial determination of soluble CD8 (sCD8), soluble IL-2 receptors (sIL-2R), and tumor necrosis factor—alpha serum levels were performed in bone marrow transplant patients upon initiation, day 0 (D0) and at D10 of an anti-IL-2 receptor (alpha chain) monoclonal antibody (B-B10) in vivo treatment for steroid-resistant grade ≥2 acute graft-versus-host disease (aGVHD). DO and D10 sCD8 serum levels correlated strongly with response to B-B10 treatment (p=.003 and .001, respectively); 76 of the patients with D0 sCD8 levels <500 U/ml responded favorably to B-B10 treatment, versus only a 30 response if the sCD8 levels were >500 U/ml (p=.02). Likewise, D0 tumor necrosis factor—alpha levels significantly correlated with subsequent response to B-B10 treatment (p=.03). D0 sIL-2R levels were not significantly different in B-B10-responsive and nonresponsive aGVHD patients. These results suggest that the serial determination of sCD8 and TNF serum levels could provide valuable predictive information as to steroid-resistant aGVHD responsiveness to anti-IL-2R treatment.

Published
1991

50. t(12;21)/ETV6-RUNX1Confers a Specific Pattern of In VivoSensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and 58951 of the EORTC Children Leukemia Group

Author

Piette, Caroline, Suciu, Stefan, Clappier, Emmanuelle, Bertrand, Yves, Plat, Genevieve, Chantrain, Christophe, Costa, Vitor, Dastugue, Nicole, Ferster, Alina, Gilotay, Caroline, Girard, Sandrine, Grardel, Nathalie, Lutz, Patrick, Mazingue, Francoise, Minckes, Odile, Munzer, Martine, Plouvier, Emmanuel, Sirvent, Nicolas, Uyttebroeck, Anne, van Roy, Nadine, Yakouben, Karima, Benoit, Yves, and Cavé, Hélène

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results